169 related articles for article (PubMed ID: 36967671)
1. Cross-reactivity between piperacillin-tazobactam and cefoperazone-sulbactam in drug-induced immune thrombocytopenia.
He X; Huang W; Wan X; Li X; Chang Q; Ding L
J Int Med Res; 2023 Mar; 51(3):3000605231162434. PubMed ID: 36967671
[TBL] [Abstract][Full Text] [Related]
2. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
3. Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients.
Chen Y; Xiang Q; Liu L
J Int Med Res; 2021 May; 49(5):3000605211019661. PubMed ID: 34057835
[TBL] [Abstract][Full Text] [Related]
4. The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia.
Lai CC; Chen WC; Kuo LK; Wang YT; Fu PK; Ku SC; Fang WF; Chen CM; Tu CY; Cheng WC; Chen CH
Medicine (Baltimore); 2023 Jul; 102(28):e34284. PubMed ID: 37443505
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: A single-centre study in Zhejiang Province, China.
Hua CZ; Wang HJ; Zhang Z; Tao XF; Li JP; Mi YM; Tang LF; Chen ZM
J Glob Antimicrob Resist; 2019 Sep; 18():47-51. PubMed ID: 30710647
[TBL] [Abstract][Full Text] [Related]
6. The effect of cefoperazone sulbactam and piperacillin tazobactam on mortality in Gram-negative nosocomial infections.
Guclu E; Kaya G; Ogutlu A; Karabay O
J Chemother; 2020 May; 32(3):118-123. PubMed ID: 32096456
[TBL] [Abstract][Full Text] [Related]
7. Rapid-Onset Thrombocytopenia Following Piperacillin-Tazobactam Reexposure.
Nguyen VD; Tourigny JF; Roy R; Brouillette D
Pharmacotherapy; 2015 Dec; 35(12):e326-30. PubMed ID: 26684560
[TBL] [Abstract][Full Text] [Related]
8. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
9. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
Wang H; Chen MJ;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
[TBL] [Abstract][Full Text] [Related]
10. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
[TBL] [Abstract][Full Text] [Related]
11. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients.
Huang CT; Chen CH; Chen WC; Wang YT; Lai CC; Fu PK; Kuo LK; Chen CM; Fang WF; Tu CY; Ku SC
Int J Antimicrob Agents; 2022 Jan; 59(1):106491. PubMed ID: 34871744
[TBL] [Abstract][Full Text] [Related]
13. Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia.
Beaulieu C; Kurczewski L; Yajnik V
J Thromb Thrombolysis; 2019 Jul; 48(1):167-170. PubMed ID: 30968302
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
[TBL] [Abstract][Full Text] [Related]
15. Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature.
Alzahrani M; Alrumaih I; Alhamad F; Abdel Warith A
Platelets; 2018 Sep; 29(6):628-631. PubMed ID: 29863943
[TBL] [Abstract][Full Text] [Related]
16. Piperacillin/tazobactam-induced immune-mediated thrombocytopenia in the intensive care unit.
Boyce K; Brar H; Stabler SN
J Clin Pharm Ther; 2016 Dec; 41(6):730-732. PubMed ID: 27670947
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients.
Frank U; Mutter J; Schmidt-Eisenlohr E; Daschner FD
Clin Microbiol Infect; 2003 Nov; 9(11):1128-32. PubMed ID: 14616732
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia.
Aynioglu A; Mutlu B; Hacihanefioglu A
Rev Esp Quimioter; 2016 Apr; 29(2):69-75. PubMed ID: 26888338
[TBL] [Abstract][Full Text] [Related]
19. Rapid-onset piperacillin-tazobactam induced thrombocytopenia.
Shaik S; Kazi HA; Ender PT
J Pharm Pract; 2015 Apr; 28(2):204-6. PubMed ID: 25609660
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
Kuo HY; Wang FD; Yen YF; Lin ML; Liu CY
New Microbiol; 2009 Jan; 32(1):49-55. PubMed ID: 19382669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
